DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Methoxyamine is an investigational drug.
There have been 6 clinical trials for Methoxyamine. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2015.
The most common disease conditions in clinical trials are Lymphoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are National Cancer Institute (NCI), Case Comprehensive Cancer Center, and [disabled in preview].
There are two US patents protecting this investigational drug and twenty-nine international patents.
Recent Clinical Trials for Methoxyamine
|Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma||National Cancer Institute (NCI)||Phase 2|
|Methoxyamine, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Phase 1|
|Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed||National Cancer Institute (NCI)||Phase 1/Phase 2|
Top disease conditions for Methoxyamine
Top clinical trial sponsors for Methoxyamine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Methoxyamine||Start Trial||Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same||Novozymes, Inc. (Davis, CA)||Start Trial|
|Methoxyamine||Start Trial||Substituted quinoxalines as FGFR kinase inhibitors||ASTEX THERAPEUTICS LTD (Cambridge, GB)||Start Trial|
|Methoxyamine||Start Trial||Polypeptides having endoglucanase activity and polynucleotides encoding same||Novozymes Inc. (Davis, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|